Collaborative Quality Improvement (C-QIP) Study

Sponsor
Public Health Foundation of India (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05196659
Collaborator
(none)
400
4
2
29
100
3.4

Study Details

Study Description

Brief Summary

The overarching goal of this study is to develop, implement, and evaluate the effect of a collaborative quality improvement (C-QIP) intervention (consisting of non-physician health workers, text messages for a healthy lifestyle, and a clinical decision support system) on processes of care and clinical outcomes among individuals with previous cardiovascular disease in India.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Integrated comprehensive cardiovascular disease management
N/A

Detailed Description

Specific objectives of this study are:
  1. To describe current practices, context, challenges, and opportunities regarding chronic management of cardiovascular disease from the patient, caregiver, provider, and health administrator perspectives in India.

  2. To assess the transferability of components of internationally successful multifaceted quality improvement strategies and chronic care models to the Indian healthcare context.

  3. To conduct a pilot study to assess the acceptability, feasibility, and implementation fidelity of the C-QIP strategy among individuals with cardiovascular disease attending out-patient clinics in India.

  4. Among individuals with cardiovascular disease, evaluate the effect of C-QIP strategy on processes of care and clinical outcomes, health-related quality of life, and costs at 1 year compared with usual care.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Individual randomized parallel-group feasibility trialIndividual randomized parallel-group feasibility trial
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Developing and Testing a Collaborative Quality ImProvement (C-QIP) Initiative for Prevention of Cardiovascular Disease in India
Anticipated Study Start Date :
Jul 1, 2022
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
No Intervention: CONTROL Group

Regular current system of care Treating physicians provided current cardiovascular disease management guidelines Patients provided a leaflet (printed information) on healthy lifestyle

Active Comparator: INTERVENTION Group

Electronic Health Record-Decision Support Software (EHR-DSS): Electronic patient health record storage Management prompts to the clinical team (following algorithms) Structured follow-up schedule with automatic reminders to patients, clinical team, and non-physician health worker Non-physician health worker-led continuity of care: - individually tailored follow-up and guidance regarding treatment adherence as well as help in resolving issues related to access, convenience, cost of care, and equity Text-message based reminders for a healthy lifestyle Patient diary containing visual assessment tool for adherence to medication (VITA) and reinforcement tool for lifestyle modification Quarterly audit and feedback to the clinical team

Behavioral: Integrated comprehensive cardiovascular disease management
Electronic Health Record-Decision Support Software (EHR-DSS): Electronic patient health record storage Management prompts to the clinical team (following algorithms) Structured follow-up schedule with automatic reminders to patients, clinical team, and non-physician health worker Non-physician health worker-led continuity of care: - individually tailored follow-up and guidance regarding treatment adherence as well as help in resolving issues related to access, convenience, cost of care, and equity Text-message based reminders for a healthy lifestyle Patient diary containing visual assessment tool for adherence to medication (VITA) and reinforcement tool for lifestyle modification Quarterly audit and feedback to the clinical team

Outcome Measures

Primary Outcome Measures

  1. Implementation outcomes [at the end of study (maximum follow-up duration 24 months).]

    Using mixed methods evaluation involving quantitative survey and in-depth interviews with the providers and patients, the primary outcome of this study is to assess the implementation outcomes such as the feasibility, and acceptability of the trial intervention defined as the extent to which providers and patients perceive the intervention strategy to be feasible to implement and useful/acceptable in their local health care setting.

  2. Prescription of evidence based medicines [at the end of study (maximum follow-up duration 24 months).]

    Through patient chart review, the study will assess the proportion of intervention arm versus control group participant's receiving evidence based medicines for cardiovascular disease management.

  3. Adherence to prescribed therapy [at the end of study (maximum follow-up duration 24 months).]

    Using validated questionnaire for medication adherence, the study will assess patient's compliance or adherence to prescribed therapy in the intervention group versus control group participants at the trial end.

Secondary Outcome Measures

  1. Change in blood pressure [at the end of study (maximum follow-up duration 24 months).]

    Mean change in systolic and diastolic blood pressure between the intervention and control group participants at the trial end.

  2. Change in low density lipoprotein cholesterol (LDLc) [at the end of study (maximum follow-up duration 24 months).]

    Mean change in LDLc between the intervention and control group participants at the trial end.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Participants should be:
  • age ≥18 years, both sexes

  • confirmed diagnosis of cardiovascular disease (ischemic heart disease, stroke, or heart failure irrespective of ejection fraction)

  • able to provide written informed consent.

Exclusion Criteria:
  • pregnant women

  • those with any serious or uncontrolled medical condition (e.g., cancer) that may restrict the patient to come for follow-up.

Contacts and Locations

Locations

Site City State Country Postal Code
1 All India Institute of Medical Sciences (AIIMS) New Delhi Delhi India 110 029
2 SDM College of Medical Sciences and Hospital Dharwad Karnataka India 580009
3 GB Pant Hospital New Delhi India 110002
4 Sir Ganga ram Hospital New Delhi India 110060

Sponsors and Collaborators

  • Public Health Foundation of India

Investigators

  • Principal Investigator: Kavita Singh, PhD, Public Health Foundation of India

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Public Health Foundation of India
ClinicalTrials.gov Identifier:
NCT05196659
Other Study ID Numbers:
  • RA1055
First Posted:
Jan 19, 2022
Last Update Posted:
Jul 6, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 6, 2022